Vinod Ravi Selected Research

Hemangiosarcoma (Angiosarcoma)

1/2022	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.
1/2022	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
1/2021	Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
11/2020	Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
1/2018	A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
8/2017	Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series.
1/2016	Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
8/2013	Vascular sarcomas.
4/2013	Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer.
5/2011	Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vinod Ravi Research Topics

Disease

32	Neoplasms (Cancer) 01/2022 - 11/2005
25	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 11/2005
11	Hemangiosarcoma (Angiosarcoma) 01/2022 - 07/2010
5	Heart Neoplasms 11/2021 - 02/2012
4	Disease Progression 01/2022 - 10/2012
4	Neoplasm Metastasis (Metastasis) 03/2021 - 10/2012
3	Aggressive Fibromatosis (Desmoid) 01/2022 - 01/2016
3	Melanoma (Melanoma, Malignant) 05/2019 - 01/2017
3	Osteosarcoma (Osteogenic Sarcoma) 01/2019 - 04/2013
3	Leiomyosarcoma 01/2017 - 04/2016
2	Diarrhea 01/2022 - 12/2018
2	Fatigue 01/2022 - 12/2018
2	Hypertension (High Blood Pressure) 01/2022 - 12/2018
2	Cardiotoxicity 01/2020 - 01/2017
2	Carcinogenesis 08/2019 - 01/2016
2	Testicular Neoplasms (Testicular Cancer) 05/2019 - 01/2017
2	Adenosarcoma 01/2018 - 11/2016
2	Ewing Sarcoma (Sarcoma, Ewing) 10/2017 - 01/2015
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2017 - 11/2005
2	Solitary Fibrous Tumors 05/2013 - 07/2010
2	Breast Neoplasms (Breast Cancer) 04/2013 - 04/2013
2	Myxoid Liposarcoma 12/2012 - 01/2012
1	Anemia 01/2022
1	Vomiting 01/2022
1	Nausea 01/2022
1	Epistaxis (Nosebleed) 01/2022
1	Headache (Headaches) 01/2022
1	Perivascular Epithelioid Cell Neoplasms 11/2021
1	Phyllodes Tumor (Cystosarcoma Phylloides) 04/2021
1	Paraganglioma (Paragangliomas) 01/2020
1	Pheochromocytoma 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 01/2019
1	Exanthema (Rash) 12/2018
1	Rare Diseases (Rare Disease) 06/2017

Drug/Important Bio-Agent (IBA)

10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2012
7	Ifosfamide FDA LinkGeneric 04/2021 - 01/2012
5	pazopanib FDA Link 01/2022 - 07/2010
5	Biological ProductsIBA 01/2021 - 11/2005
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 07/2010
4	Gemcitabine FDA Link 01/2020 - 01/2015
3	Phosphotransferases (Kinase)IBA 01/2022 - 04/2014
3	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 07/2010
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2018 - 11/2005
3	DNA (Deoxyribonucleic Acid)IBA 06/2017 - 01/2015
3	Docetaxel (Taxotere)FDA Link 01/2017 - 01/2015
2	pembrolizumabIBA 01/2022 - 01/2020
2	Estrogen ReceptorsIBA 01/2022 - 01/2018
2	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 11/2005
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 11/2017
2	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 11/2020 - 08/2019
2	ParaffinIBA 01/2020 - 01/2016
2	AntigensIBA 05/2019 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 04/2016
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2018 - 01/2016
2	Bevacizumab (Avastin)FDA Link 01/2018 - 07/2010
2	Everolimus FDA Link 11/2017 - 01/2015
2	Vincristine (Oncovin)FDA LinkGeneric 10/2017 - 01/2015
2	Denosumab FDA Link 07/2017 - 01/2015
2	Cisplatin (Platino)FDA LinkGeneric 01/2015 - 01/2015
1	carotuximabIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	Vinca AlkaloidsIBA 01/2022
1	Sirolimus (Rapamycin)FDA Link 11/2021
1	AlbuminsIBA 03/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	trametinibIBA 01/2021
1	Mitogen-Activated Protein KinasesIBA 01/2021
1	cediranib (AZD2171)IBA 01/2021
1	AnthracyclinesIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	GenieIBA 08/2019
1	RadiumIBA 01/2019
1	TabletsIBA 12/2018
1	Antineoplastic Agents (Antineoplastics)IBA 10/2018
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2018
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Vorinostat FDA Link 11/2017
1	Histone Deacetylases (Histone Deacetylase)IBA 11/2017
1	Lapatinib (GW572016)FDA Link 11/2017
1	Trastuzumab (Herceptin)FDA Link 11/2017
1	MART-1 AntigenIBA 08/2017
1	Monophenol Monooxygenase (Tyrosinase)IBA 08/2017
1	Pharmaceutical PreparationsIBA 06/2017
1	AngiopoietinsIBA 01/2017
1	palbociclibIBA 01/2017
1	Histocompatibility Antigens Class IIBA 01/2017

Therapy/Procedure

34	Therapeutics 01/2022 - 11/2005
16	Drug Therapy (Chemotherapy) 01/2022 - 11/2005
5	Immunotherapy 01/2022 - 01/2017
5	Radiotherapy 11/2016 - 05/2011
2	Pneumonectomy (Lung Volume Reduction) 11/2021 - 09/2014
2	Precision Medicine 03/2021 - 11/2020
2	Hysterectomy 01/2018 - 11/2016
2	Lymph Node Excision (Lymph Node Dissection) 01/2018 - 11/2016
2	Salpingo-oophorectomy 01/2018 - 11/2016
2	Adjuvant Chemotherapy 11/2016 - 04/2012
1	Endarterectomy (Thromboendarterectomy) 11/2021
1	Neoadjuvant Therapy 07/2017
1	Investigational Therapies (Experimental Therapy) 06/2017